We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Loss of Endothelial Cell Enzyme Restores Sensitivity to Chemotherapy and Radiation in Nearby Tumor Cells

By LabMedica International staff writers
Posted on 04 Aug 2014
Cancer researchers have found that an enzyme produced by cells in the blood vessels that serve tumors triggers the release of signaling molecules that stimulate the repair of damage to the tumor cells caused by treatment with radiation or chemotherapeutic agents.

Investigators at Queen Mary University (London, United Kingdom) examined the role of the enzyme focal adhesion kinase (FAK) in noncancerous endothelial cells in regions of tumor growth.

FAK is a 125-kDa protein that is known to participate in focal adhesion dynamics between cells with a role in motility and cell survival. More...
FAK is a highly conserved, nonreceptor tyrosine kinase originally identified as a substrate for the oncogene protein, tyrosine kinase v-src. This cytoplasmic kinase has been implicated in diverse cellular roles including cell locomotion, mitogen response, and cell survival. FAK is typically located at structures known as focal adhesions, which are multiprotein structures that link the extracellular matrix (ECM) to the cytoplasmic cytoskeleton. It has been shown that when FAK was blocked, breast cancer cells became less metastatic due to decreased mobility.

In the current study, the investigators blocked FAK activity in the cells lining blood vessels in a mouse tumor model. They found that deletion of FAK in endothelial cells had no apparent effect on blood vessel function but induced increased apoptosis and decreased proliferation of tumor cells in doxorubicin- and radiotherapy-treated mice. Mechanistically, they demonstrated that endothelial-cell FAK was required for DNA-damage-induced NF-kappaB activation in vivo and in vitro and for the production of cytokines from endothelial cells. Loss of endothelial-cell FAK reduced DNA-damage-induced cytokine production, thus enhancing chemosensitization of tumor cells to DNA-damaging therapies in vitro and in vivo.

Additional data published in the July 27, 2014, online edition of the journal Nature revealed that that low blood vessel FAK expression was associated with complete remission in human lymphoma.

First author Dr. Bernardo Tavora, a postdoctoral associate at Queen Mary University, said, "This work shows that sensitivity to cancer treatment is related to our own body mistakenly trying to shield the cancer from cell-killing effects caused by radiotherapy and chemotherapy. Although taking out FAK from blood vessels will not destroy the cancer by itself, it can remove the barrier cancer uses to protect itself from treatment."

Related Links:

Queen Mary University




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.